ESR1 and breast cancer: Triple-negative breast cancer (TNBC) (ERα−, PR− and HER2−) accounts for approximately 15% of all BC cases and is characterized by shorter survival and an early peak of distant recurrence (Manjunath and Choudhary, 2021).